Aripiprazole Augmentation May Improve Remission Rates in MDD
The Carlat Psychiatry Report, Volume 15, Number 1, November 2017
Ricardo Arechiga, PharmD candidate (2018)
Mr. Arechiga has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
It seems like an endless debate: When a patient does not respond to the first trial of an antidepressant, what should we do? Switch to something else? Augment with another agent? If the latter, how often should that augmenting agent be an atypical antipsychotic?